VA
NEO icon

Vident Advisory’s NeoGenomics NEO Stock Holding History

Vident Advisory’s Portfolio NEO Stock Details NEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-52,441
Closed -$774K – 1514
2024
Q3 		$774K Buy
52,441
+2,277
+5% +$35.6K 0.02% 729
2024
Q2 		$696K Buy
50,164
+14,556
+41% +$206K 0.02% 727
2024
Q1 		$560K Buy
35,608
+5,971
+20% +$92.2K 0.01% 777
2023
Q4 		$480K Buy
29,637
+15,336
+107% +$251K 0.01% 792
2023
Q3 		$176K Buy
+14,301
New +$213K 0.01% 1140

Other funds holding NEO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vident Advisory's NEO Position: Q4 2024 in Review

Vident Advisory sold out of NeoGenomics (NEO) in Q4 2024, closing a stake of 52,441 shares — an estimated $774K sold.

Vident Advisory first reported a position in NEO in Q3 2023 and held it in 5 quarters. The position peaked at $774K in Q3 2024. 253 funds tracked by Wall St. Rank hold NEO as of Q4 2024.

  • Vident Advisory reported no remaining NeoGenomics position as of Q4 2024 after selling out during the quarter.
  • Vident Advisory sold 52,441 NeoGenomics shares in Q4 2024, an estimated $774K.
  • Vident Advisory first reported a position in NeoGenomics in Q3 2023 and held it in 5 quarters.
  • Vident Advisory's NeoGenomics position peaked at $774K in Q3 2024.
  • 253 funds tracked by Wall St. Rank held NeoGenomics as of Q4 2024.

Based on Vident Advisory's 13F filing for Q4 2024, filed 14 Feb 2025.